Sermorelin is a synthetic, amidated 29-amino-acid peptide corresponding to the biologically active amino-terminal segment of human growth hormone-releasing hormone (GHRH). It is a distinct molecule; the shared “growth hormone” vocabulary does not make Sermorelin interchangeable with CJC-1295, ipamorelin, tesamorelin, or a blended product.
Historical FDA-approved Geref presentations had specific strengths and labeled uses, including pediatric growth hormone deficiency and diagnostic evaluation of pituitary growth hormone secretion. Those approvals were withdrawn in 2009 at the sponsor’s request. FDA later determined that the products had not been withdrawn for safety or effectiveness reasons, but they remain on the discontinued-drug list.
Many products currently described as Sermorelin are compounded preparations. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and different pharmacies may dispense different total vial amounts, concentrations, diluents, or combination products. A number copied from another vial, clinic, or website therefore cannot establish the correct volume for the product in front of you.
This page solves only the arithmetic after the relevant values are known. It divides total vial mass by total liquid volume to calculate concentration, converts the entered target mass to milliliters, and then converts milliliters to U-100 markings. It cannot verify identity, potency, sterility, compatibility, route, clinical suitability, or the target amount itself.